Sanjoy Dutta, Ph.D.: The Beginning of the ADA Scientific Sessions

Published June 8, 2019 in Beta cell replacement, Conference

The ADA’s Scientific Sessions has begun! Here, in the first recap, is Sanjoy Dutta, Ph.D., who highlights the beta cell replacement therapies. Happy viewing!

Top Type 1 Diabetes Advances of Fiscal Year 2023

JDRF highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.

Read More about Top Type 1 Diabetes Advances of Fiscal Year 2023
JDRF Collaboration Leads to Next-Generation Cell Therapy Research

Aspect and Novo Nordisk announce a partnership, using Aspect’s bioprinting technology and Novo Nordisk’s expertise, to develop treatments for diabetes.

Read More about JDRF Collaboration Leads to Next-Generation Cell Therapy Research
Cell Therapy Moves Forward Across the Pipeline

Beta cell replacement therapies aim to overcome the obstacles to realize their potential, but several approaches are making them a thing of the past.

Read More about Cell Therapy Moves Forward Across the Pipeline